Skip to main content

Table 4 Multivariate analysis results (excluding Fludarabine/Busulfan-based conditioning regimens)

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

 

Number

Relative risk

95%CI

lower limit

95%CI

upper limit

p value

Acute GVHD (grades 3–4)a

     

 Non-rituximab RIC

647

1

  

0.58

 Rituximab-containing RIC

356

0.89

0.59

1.34

 

Chronic GVHD

     

 Non-rituximab RIC

635

1

  

0.51

 Rituximab-containing RIC

349

1.07

0..87

1.30

 

Non-relapse mortality

     

 Non-rituximab RIC

638

1

  

0.14

 Rituximab-containing RIC

346

0.79

0.57

1.08

 

Progression/relapse

     

 Non-rituximab RIC

638

1

  

0.13

 Rituximab-containing RIC

346

0.82

0.64

1.06

 

PFS

     

 Non-rituximab RIC

638

1

  

0.002

 Rituximab-containing RIC

346

0.73

0.60

0.89

 

Mortality

     

 Non-rituximab RIC

662

1

  

0.02

 Rituximab-containing RIC

358

0.76

0.60

0.96

 
  1. Abbreviations: GVHD graft-versus-host disease, RIC reduced-intensity conditioning
  2. aAcute GVHD models used logistic regression